Clinical Trial Corner

An ongoing phase 1 trial is analyzing the use of a novel cancer vaccine plus the immunotherapy agent, Keytruda, for patients with triple-negative breast cancer.

Researchers conducting this trial will compare zipalertinib plus chemotherapy with chemotherapy alone in patients with previously untreated, locally advanced or metastatic non-small cell lung cancer with the EGFR exon 20 insertion mutation.

A patient with glioblastoma, a type of brain cancer, was dosed with a novel combination immunotherapy as part of a phase 2b trial.

Treatment with a CAR-M cell therapy plus Keytruda is being assessed in a phase 1 study in patients with HER2-overexpressed tumors.

The TILVANCE-301trial, expected to be completed in 2030, is the latest study of what has been described as one of the “phenomenal discoveries in melanoma.”

This summer, a trial will kick off studying ISM3091 in patients with advanced solid tumors.

Work is underway in the global phase 3 HARMONi study evaluating the combination of ivonescimab and chemotherapy in the treatment of patients with EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer.

The phase 3 HARMONi trial recently kicked off, studying ivonescimab plus chemotherapy for EGFR-mutant non-small cell lung cancer.

A clinical trial studying an accelerated dose of Besremi recently kicked off.

OKN-007 is being evaluated both alone and in combination with chemotherapy for patients with glioma or glioblastoma — both types of brain cancer.

The phase 3 Pragmatica-Lung study evaluating Cyramza and Keytruda has broader eligibility criteria than many other trials, expanding access to more patients and clinicians.

Researchers conducting the VISTA-101 study will assess the safety and efficacy of KVA12123 alone and with Keytruda, in addition to determining the recommended dose of the therapy.

A pharmaceutical company initiated a phase 1b study in patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.

A phase 1/1b trial will examine PRGN-3007 in patients with ROR1-positive hematologic and solid cancers.

The phase 3 ARASTEP trial will investigate Nubeqa plus androgen-deprivation therapy in certain patients with hormone-sensitive prostate cancer.

Pre- and post-menopausal patients with locally advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation are eligible to participate in the next round of Fablyn’s upcoming clinical trial.

The first patient was enrolled in a three-drug clinical trial, which researchers hope will lend insight into immunotherapy resistance in lung cancer.

The first patient has been enrolled in a clinical trial evaluating IMNN-001, an immunotherapy, combined with Avastin for the treatment of advanced ovarian cancer.

Researchers are recruiting patients with ER-positive, HER2-negative breast cancer to participate in a trial evaluating (Z)-endoxifen.

A clinical trial is currently enrolling patients who are experiencing hand-foot skin reaction as a result of kidney cancer treatment.

A clinical trial just kicked off, analyzing Padcev in patients with advanced, unresectable bladder cancer.

Researchers conducting a phase 2 trial recently dosed the first patients with a novel menin inhibitor for the treatment of patients with NPM1-mutant relapsed or refractory acute myeloid leukemia.

After promising phase 1 results, ART0380 will be studied in a randomized phase 2 trial for patients with platinum-resistant ovarian cancer.

The first patient was dosed with lerapolturev in a phase 1/2 clinical trial evaluating the drug in patients with bladder cancer and other solid tumors.

A phase 3 trial will test datopotamab deruxtecan in combination with Keytruda with or without chemotherapy for certain patients with metastatic non-small cell lung cancer.

The treatment previously demonstrated significantly improved overall survival for patients with recurrent glioblastoma in a phase 1 study.

VIC-1911 will be studied alone or with Lumakras in patients with KRAS G12C-mutant non-small cell lung cancer.

Researchers just launched a phase 2 trial evaluating iadademstat plus paclitaxel in patients with relapsed/refractory neuroendocrine cancer, including those with small cell lung cancer.